Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
Abstract Background The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relates to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections.Methods Among 11822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 31 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisonsResults Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups.Conclusions The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 08. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flisiak, Robert [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2022.07.05.22277227 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI036457795 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI036457795 | ||
| 003 | DE-627 | ||
| 005 | 20230429080525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220708s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.07.05.22277227 |2 doi | |
| 035 | |a (DE-627)XBI036457795 | ||
| 035 | |a (biorXiv)10.1101/2022.07.05.22277227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Flisiak, Robert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relates to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections.Methods Among 11822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 31 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisonsResults Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups.Conclusions The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age. | ||
| 700 | 1 | |a Zarębska-Michaluk, Dorota |e verfasserin |4 aut | |
| 700 | 1 | |a Rogalska, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Kryńska, Justyna Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalska, Justyna |e verfasserin |4 aut | |
| 700 | 1 | |a Dutkiewicz, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrowolska, Krystyna |e verfasserin |4 aut | |
| 700 | 1 | |a Jaroszewicz, Jerzy |e verfasserin |4 aut | |
| 700 | 1 | |a Moniuszko-Malinowska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rorat, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Podlasin, Regina |e verfasserin |4 aut | |
| 700 | 1 | |a Tronina, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Rzymski, Piotr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 08. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:08 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.07.05.22277227 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 08 |c 07 | ||
| 953 | |2 045F |a 570 | ||